Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06442475 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

NCT06442475 · ClinicalTrials.gov record · last posted 2026-08-27

Low Dose Mosunetuzumab for the Treatment of Patients With Indolent B-Cell Lymphoma

Name: Low Dose Mosunetuzumab for the Treatment of Patients With Indolent B-Cell Lymphoma — clinical trial record (NCT06442475)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

StatusRecruiting

PhasePhase 2

SponsorUniversity of Washington

Started2024-08-29

View on ClinicalTrials.gov ↗

from the ClinicalTrials.gov record

This phase II trial tests the safety, side effects and effectiveness of mosunetuzumab in treating patients with slow growing (indolent) B-cell lymphoma. Mosunetuzumab is a monoclonal antibody that may interfere with the ability of tumor cells to grow and spread.

Protocol amendment history 2 changes detected by DataLookout

2026-08-28

Primary completion pushed: 2026-08-12 → 2027-08-12

2026-08-28

Completion pushed: 2027-02-12 → 2028-02-12

Trial Details

NCT Number	NCT06442475
Lead Sponsor	University of Washington
Conditions	Ann Arbor Stage II Follicular Lymphoma, Ann Arbor Stage II Marginal Zone Lymphoma, Ann Arbor Stage III Follicular Lymphoma, Ann Arbor Stage III Marginal Zone Lymphoma, Ann Arbor Stage IV Follicular Lymphoma, Ann Arbor Stage IV Marginal Zone Lymphoma, Grade 1 Follicular Lymphoma, Grade 2 Follicular Lymphoma +1 more
Enrollment	20 participants
Start Date	2024-08-29
Primary Completion	2027-08-12 (estimated)
Study Completion	2028-02-12 (estimated)
Updated on ClinicalTrials.gov	2026-08-27